Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer

作者：Hiroshige Tasuku; Eguchi Yoshiro; Yoshizumi Osamu; Chikui Katsuaki; Kumagai Hisaji; Kawaguchi Yoshihiro; Onishi Rei; Hayashi Tokumasa; Watanabe Kouta; Mitani Tomotaro; Saito Koujiro; Igawa Tsukasa

来源：Oncology Letters, 2018, 15(5): 6806-6814.

DOI：10.3892/ol.2018.8263

• baseline prostate-specific antigen
• castration-resistant prostate cancer
• abiraterone acetate

The aim of the present study was to investigate the prognostic factors associated with progression-free survival (PFS) and overall survival (OS) times in patients with castration-resistant prostate cancer (CRPC) who received treatment with abiraterone acetate (AA) in routine clinical settings. A total of 93 patients treated with AA between September 2014 and February 2017 were selected and their medical records were analyzed retrospectively. The median PFS time of docetaxel (DTX)-naive patients was 171 days, and that of post-DTX patients was 56 days. The OS time of DTX-naive patients did not reach the median. The median OS time of post-DTX patients was 761 days. Multivariate analyses identified baseline prostate-specific antigen (PSA) level prior to treatment with AA and the PSA response rate as independent prognostic factors for PFS time, and baseline PSA prior to treatment with AA as the only independent prognostic factor for OS time. The results of the present study indicate that the baseline PSA level prior to treatment with AA is a notable prognostic factor in patients with CRPC.

• 出版日期2018-5